IL-15 and IL-17F are differentially regulated and expressed in mycosis fungoides (MF)

Cell Cycle

Volumn 13, Issue 8, 2014, Pages 1306-1312

  Willerslev Olsen, Andreas ^a   Litvinov, Ivan V ^b   Fredholm, Simon M ^a   Petersen, David L ^a   Sibbesen, Nina A ^a   Gniadecki, Robert ^c   Zhang, Qian ^d   Bonefeld, Charlotte M ^a   Wasik, Mariusz A ^d   Geisler, Carsten ^a   Zhou, Youwen ^e   Woetmann, Anders ^a   Sasseville, Denis ^b   Krejsgaard, Thorbjørn ^a   Ødum, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c Mental Health Services CPH   (Denmark)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

CTCL; IL 15; IL 17F; Jak3; MF; STAT3

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 17F; INTERLEUKIN 5; JANUS KINASE 3; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN;

ARTICLE; CELL LINE; DISEASE COURSE; HUMAN; HUMAN CELL; MYCOSIS FUNGOIDES; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SKIN DEFECT; T LYMPHOCYTE; CUTANEOUS T CELL LYMPHOMA; GENETICS; METABOLISM; PATHOLOGY; SKIN TUMOR; TUMOR CELL LINE;

CELL LINE, TUMOR; HUMANS; INTERLEUKIN-15; INTERLEUKIN-17; LYMPHOMA, T-CELL, CUTANEOUS; MYCOSIS FUNGOIDES; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR;

EID: 84899113324     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.28256     Document Type: Article

References (52)

1. Willemze R. Thirty years of progress in cutaneous lymphoma research. G Ital Dermatol Venereol 2012; 147:515-21; PMID:23149697
2. Imam MH, Shenoy PJ, Flowers CR, Phillips A, Lechowicz MJ. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States. Leuk Lymphoma 2013; 54:752-9; PMID:23004352; http://dx.doi.org/10.3109/10428194.2012. 729831
3. Döbbeling U, Dummer R, Laine E, Potoczna N, Qin JZ, Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998; 92:252-8; PMID:9639524
4. Michalak-Stoma A, Pietrzak A, Szepietowski JC, Zalewska-Janowska A, Paszkowski T, Chodorowska G. Cytokine network in psoriasis revisited. Eur Cytokine Netw 2011; 22:160-8; PMID:22236965
5. Elder JT. IL-15 and psoriasis: another genetic link to Th17? J Invest Dermatol 2007; 127:2495-7; PMID:17934500; http://dx.doi.org/10.1038/sj.jid. 5700855
6. Qin JZ, Dummer R, Burg G, Döbbeling U. Constitutive and interleukin-7/interleukin-15 stimulated DNA binding of Myc, Jun, and novel Myc-like proteins in cutaneous T-cell lymphoma cells. Blood 1999; 93:260-7; PMID:9864169
7. Krejsgaard T, Ralfkiaer U, Clasen-Linde E, Eriksen KW, Kopp KL, Bonefeld CM, Geisler C, Dabelsteen S, Wasik MA, Ralfkiaer E, et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol 2011; 131:1331-8; PMID:21346774; http://dx.doi.org/10.1038/ jid.2011.27
8. Krejsgaard T, Litvinov IV, Wang Y, Xia L, Willerslev-Olsen A, Koralov SB, Kopp KL, Bonefeld CM, Wasik MA, Geisler C, et al. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood 2013; 122:943-50; PMID:23801634; http://dx.doi.org/10.1182/blood-2013-01-480889
9. Caruso R, Costanzo A, Monteleone G. Pathogenic role of interleukin-21 in psoriasis. Cell Cycle 2009; 8:3629-30; PMID:19884801; http://dx.doi.org/10.4161/ cc.8.22.9964
10. Kasprzycka M, Zhang Q, Witkiewicz A, Marzec M, Potoczek M, Liu X, Wang HY, Milone M, Basu S, Mauger J, et al. Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol 2008; 181:2506-12; PMID:18684941
11. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 2013; 22:993-1005; PMID:23731078; http://dx.doi.org/10.1517/ 13543784.2013.806483
12. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999; 141:1054-60; PMID:10606852; http://dx.doi.org/10.1046/j.1365-2133.1999.03205.x
13. Chua RA, Arbiser JL. The role of angiogenesis in the pathogenesis of psoriasis. Autoimmunity 2009; 42:574-9; PMID:19863376; http://dx.doi.org/10. 1080/08916930903002461
14. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Lovato P, Labuda T, Eriksen KW, Zhang Q, Becker JC, Ødum N. Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma. Leukemia 2006; 20:1759-66; PMID:16932349; http://dx.doi.org/10.1038/sj.leu.2404350
15. Karpova MB, Fujii K, Jenni D, Dummer R, Urosevic-Maiwald M. Evaluation of lymphangiogenic markers in Sézary syndrome. Leuk Lymphoma 2011; 52:491-501; PMID:20846094; http://dx.doi.org/10.3109/10428194.2010.517877
16. Pedersen IH, Willerslev-Olsen A, Vetter-Kauczok C, Krejsgaard T, Lauenborg B, Kopp KL, Geisler C, Bonefeld CM, Zhang Q, Wasik MA, et al. Vascular endothelial growth factor receptor-3 expression in mycosis fungoides. Leuk Lymphoma 2013; 54:819-26; PMID:22946664; http://dx.doi.org/10.3109/10428194. 2012.726720
17. Bianchi L, Farrace MG, Nini G, Piacentini M. Abnormal Bcl-2 and "tissue" transglutaminase expression in psoriatic skin. J Invest Dermatol 1994; 103:829-33; PMID:7798623; http://dx.doi.org/10.1111/1523-1747. ep12413590
18. Reefman E, Limburg PC, Kallenberg CG, Bijl M. Apoptosis in human skin: role in pathogenesis of various diseases and relevance for therapy. Ann N Y Acad Sci 2005; 1051:52-63; PMID:16126944; http://dx.doi.org/10.1196/annals.1361.046
19. Eriksen KW, Lovato P, Skov L, Krejsgaard T, Kaltoft K, Geisler C, Ødum N. Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol 2005; 125:936-44; PMID:16297193; http://dx.doi.org/10.1111/j. 0022-202X.2005.23864.x
20. Eriksen KW, Woetmann A, Skov L, Krejsgaard T, Bovin LF, Hansen ML, Grønbaek K, Billestrup N, Nissen MH, Geisler C, et al. Deficient SOCS3 and SHP-1 expression in psoriatic T cells. J Invest Dermatol 2010; 130:1590-7; PMID:20130595; http://dx.doi.org/10.1038/jid.2010.6
21. Brender C, Lovato P, Sommer VH, Woetmann A, Mathiesen AM, Geisler C, Wasik M, Ødum N. Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNalpha. Leukemia 2005; 19:209-13; PMID:15618960; http://dx.doi.org/10.1038/sj.leu.2403610
22. Meisgen F, Xu N, Wei T, Janson PC, Obad S, Broom O, Nagy N, Kauppinen S, Kemény L, Ståhle M, et al. MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp Dermatol 2012; 21:312-4; PMID:22417311; http://dx.doi.org/10.1111/j.1600-0625.2012.01462.x
23. Sonkoly E, Ståhle M, Pivarcsi A. MicroRNAs: novel regulators in skin inflammation. Clin Exp Dermatol 2008; 33:312-5; PMID:18419608; http://dx.doi.org/10.1111/j.1365-2230.2008.02804.x
24. Ralfkiaer U, Hagedorn PH, Bangsgaard N, Løvendorf MB, Ahler CB, Svensson L, Kopp KL, Vennegaard MT, Lauenborg B, Zibert JR, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood 2011; 118:5891-900; PMID:21865341; http://dx.doi.org/10.1182/blood-2011-06-358382
25. Kopp KL, Ralfkiaer U, Gjerdrum LM, Helvad R, Pedersen IH, Litman T, Jønson L, Hagedorn PH, Krejsgaard T, Gniadecki R, et al. STAT5-mediated expression of oncogenic miR-155 in cutaneous T-cell lymphoma. Cell Cycle 2013; 12:1939-47; PMID:23676217; http://dx.doi.org/10.4161/cc.24987
26. Eyerich K, Novak N. Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy 2013; 68:974-82; PMID:23889510; http://dx.doi.org/10.1111/all. 12184
27. Asadullah K, Haeussler-Quade A, Gellrich S, Hanneken S, Hansen-Hagge TE, Döcke WD, Volk HD, Sterry W. IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. Exp Dermatol 2000; 9:248-51; PMID:10949545; http://dx.doi.org/10.1034/j.1600-0625. 2000.009004248.x
28. Qin JZ, Zhang CL, Kamarashev J, Dummer R, Burg G, Döbbeling U. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood 2001; 98:2778-83; PMID:11675351; http://dx.doi.org/10.1182/blood.V98.9.2778
29. Leroy S, Dubois S, Tenaud I, Chebassier N, Godard A, Jacques Y, Dréno B. Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Br J Dermatol 2001; 144:1016-23; PMID:11359391; http://dx.doi.org/10.1046/j.1365-2133.2001.04192.x
30. Litvinov IV, Jones DA, Sasseville D, Kupper TS. Transcriptional profiles predict disease outcome in patients with cutaneous T-cell lymphoma. Clin Cancer Res 2010; 16:2106-14; PMID:20233883; http://dx.doi.org/10.1158/1078-0432.CCR-09- 2879
31. Woetmann A, Lovato P, Eriksen KW, Krejsgaard T, Labuda T, Zhang Q, Mathiesen AM, Geisler C, Svejgaard A, Wasik MA, et al. Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood 2007; 109:3325-32; PMID:17179233; http://dx.doi.org/10.1182/blood-2006-04- 017863
32. Krejsgaard T, Gjerdrum LM, Ralfkiaer E, Lauenborg B, Eriksen KW, Mathiesen AM, Bovin LF, Gniadecki R, Geisler C, Ryder LP, et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. Leukemia 2008; 22:2230-9; PMID:18769452; http://dx.doi.org/10.1038/leu.2008.224
33. Søndergaard H, Frederiksen KS, Thygesen P, Galsgaard ED, Skak K, Kristjansen PE, Odum N, Kragh M. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors. Cancer Immunol Immunother 2007; 56:1417-28; PMID:17285290; http://dx.doi.org/10. 1007/s00262-007-0285-4
34. Lauenborg B, Kopp K, Krejsgaard T, Eriksen KW, Geisler C, Dabelsteen S, Gniadecki R, Zhang Q, Wasik MA, Woetmann A, et al. Programmed cell death-10 enhances proliferation and protects malignant T cells from apoptosis. APMIS 2010; 118:719-28; PMID:20854465; http://dx.doi.org/10.1111/j.1600-0463.2010. 02669.x
35. Geisler C, Dietrich J, Nielsen BL, Kastrup J, Lauritsen JP, Odum N, Christensen MD. Leucine-based receptor sorting motifs are dependent on the spacing relative to the plasma membrane. J Biol Chem 1998; 273:21316-23; PMID:9694892; http://dx.doi.org/10.1074/jbc.273.33.21316
36. Theander TG, Kharazmi A, Pedersen BK, Christensen LD, Tvede N, Poulsen LK, Odum N, Svenson M, Bendtzen K. Inhibition of human lymphocyte proliferation and cleavage of interleukin-2 by Pseudomonas aeruginosa proteases. Infect Immun 1988; 56:1673-7; PMID:3133317
37. Litvinov IV, Kupper TS, Sasseville D. The role of AHI1 and CDKN1C in cutaneous T-cell lymphoma progression. Exp Dermatol 2012; 21:964-6; PMID:23171462; http://dx.doi.org/10.1111/exd.12039
38. Litvinov IV, Zhou Y, Kupper TS, Sasseville D. Loss of BCL7A expression correlates with poor disease prognosis in patients with early-stage cutaneous T-cell lymphoma. Leuk Lymphoma 2013; 54:653-4; PMID:22856870; http://dx.doi.org/10.3109/10428194.2012.717695
39. Krejsgaard T, Vetter-Kauczok CS, Woetmann A, Kneitz H, Eriksen KW, Lovato P, Zhang Q, Wasik MA, Geisler C, Ralfkiaer E, et al. Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma. Blood 2009; 113:5896-904; PMID:19351960; http://dx.doi.org/10.1182/blood-2008-09-181024
40. van Kester MS, Borg MK, Zoutman WH, Out-Luiting JJ, Jansen PM, Dreef EJ, Vermeer MH, van Doorn R, Willemze R, Tensen CP. A meta-analysis of gene expression data identifies a molecular signature characteristic for tumor-stage mycosis fungoides. J Invest Dermatol 2012; 132:2050-9; PMID:22513784; http://dx.doi.org/10.1038/jid.2012.117
41. Thakur S, Lin HC, Tseng WT, Kumar S, Bravo R, Foss F, Gélinas C, Rabson AB. Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells. Oncogene 1994; 9:2335-44; PMID:8036016
42. Chang TP, Vancurova I. NFκB function and regulation in cutaneous T-cell lymphoma. Am J Cancer Res 2013; 3:433-45; PMID:24224122
43. Kopp KL, Kauczok CS, Lauenborg B, Krejsgaard T, Eriksen KW, Zhang Q, Wasik MA, Geisler C, Ralfkiaer E, Becker JC, et al. COX-2-dependent PGE(2) acts as a growth factor in mycosis fungoides (MF). Leukemia 2010; 24:1179-85; PMID:20428208; http://dx.doi.org/10.1038/leu.2010.66
44. Braun FK, Al-Yacoub N, Plötz M, Möbs M, Sterry W, Eberle J. Nonsteroidal anti-inflammatory drugs induce apoptosis in cutaneous T-cell lymphoma cells and enhance their sensitivity for TNF-related apoptosis-inducing ligand. J Invest Dermatol 2012; 132:429-39; PMID:22011910; http://dx.doi.org/10. 1038/jid.2011.316
45. Leroy S, Dubois S, Tenaud I, Chebassier N, Godard A, Jacques Y, Dréno B. Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). Br J Dermatol 2001; 144:1016-23; PMID:11359391; http://dx.doi.org/10.1046/j.1365-2133.2001.04192.x
46. Sugaya M, Nakamura K, Tamaki K. Serum interleukin-15 levels are not elevated in patients with stage I and II mycosis fungoides. Acta Derm Venereol 2000; 80:455; PMID:11243648
47. Yamanaka K, Clark R, Rich B, Dowgiert R, Hirahara K, Hurwitz D, Shibata M, Mirchandani N, Jones DA, Goddard DS, et al. Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood 2006; 107:2440-5; PMID:16322477; http://dx.doi.org/10.1182/blood-2005-03- 1139
48. Wysocka M, Benoit BM, Newton S, Azzoni L, Montaner LJ, Rook AH. Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 2004; 104:4142-9; PMID:15328153; http://dx.doi.org/10.1182/blood-2004-03-1190
49. Wysocka M, Dawany N, Benoit B, Kossenkov AV, Troxel AB, Gelfand JM, Sell MK, Showe LC, Rook AH. Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon-α: implications for therapy of cutaneous T-cell lymphoma. Leuk Lymphoma 2011; 52:1970-9; PMID:21942329; http://dx.doi.org/10.3109/10428194.2011.582202
50. Willerslev-Olsen A, Krejsgaard T, Lindahl LM, Bonefeld CM, Wasik MA, Koralov SB, Geisler C, Kilian M, Iversen L, Woetmann A, et al. Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. Toxins (Basel) 2013; 5:1402-21; PMID:23949004; http://dx.doi.org/10.3390/toxins5081402
51. Hansen ML, Woetmann A, Krejsgaard T, Kopp KL, Søkilde R, Litman T, Straten PT, Geisler C, Wasik MA, Odum N, et al. IFN-α primes T- and NK-cells for IL-15-mediated signaling and cytotoxicity. Mol Immunol 2011; 48:2087-93; PMID:21813181; http://dx.doi.org/10.1016/j.molimm.2011.07.008
52. Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 2013; 19:1114-23; PMID:23913124; http://dx.doi.org/10.1038/nm.3291